March 19, 2018 08:03 AM EDT
R&D

Heron's pain drug nails PhI­II, prep­ping the com­pa­ny for NDA lat­er this year

Brittany Meiling

San Diego’s Heron Ther­a­peu­tics $HRTX is on a roll, to­day trum­pet­ing good news from its Phase III tri­al in post-op­er­a­tive pain. The promis­ing da­ta will …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Mer­ck buys in­to PD-1/VEGF space as Sum­mit comes for Keytru­da

Ex­clu­sive: As­cid­i­an CEO Michael Ehlers leaves Ap­ple Tree Part­ners for MPM BioIm­pact

FDA ap­proves PTC’s ul­tra-rare dis­ease gene ther­a­py for broad­er pa­tient pop­u­la­tion than Eu­rope

GSK makes case for Blenrep's re­turn with new blood can­cer sur­vival da­ta

Met­sera rais­es $215M for stud­ies of GLP-1 and amylin obe­si­ty drugs

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times